January 2019

Advanced Control Specialty Formulary™

The **CVS Caremark® Advanced Control Specialty Formulary™** is a guide within select therapeutic categories for clients, plan members and health care providers. **Generics should be considered the first line of prescribing**. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase *Italics*, and generic products in lowercase *italics*.

PLAN MEMBER

Your benefit plan provides you with a prescription benefit program administered by CVS Caremark. Ask your doctor to consider prescribing, when medically appropriate, a preferred medicine from this list. Take this list along when you or a covered family member sees a doctor.

Please note:

- Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the U.S. Food and Drug Administration (FDA) may not be covered upon release to the market.
- Your prescription benefit plan design may alter coverage of certain products or vary copay[1] amounts based on the condition being treated.
- You may be responsible for the full cost of non-formulary products that are removed from coverage.
- For specific information regarding your prescription benefit coverage and copay[1] information, please visit www.caremark.com or contact a CVS Caremark Customer Care representative.
- CVS Caremark may contact your doctor after receiving your prescription to request consideration of a drug list product or generic equivalent. This may result in your doctor prescribing, when medically appropriate, a different brand-name product or generic equivalent in place of your original prescription.
- In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market.

HEALTH CARE PROVIDER

Your patient is covered under a prescription benefit plan administered by CVS Caremark. As a way to help manage health care costs, authorize generic substitution whenever possible. If you believe a brand-name product is necessary, consider prescribing a brand name on this list.

Please note:

- Generics should be considered the first line of prescribing.
- The member's prescription benefit plan design may alter coverage of certain products or vary copay[1] amounts based on the condition being treated.
- This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. The member's specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the FDA may not be covered upon release to the market.
- The member's prescription benefit plan may have a different copay[1] for specific products on the list.
- Unless specifically indicated, drug list products will include all dosage forms.
- Log in to www.caremark.com to check coverage and copay[1] information for a specific medicine.

ANALGESICS

VISCOSUPPLEMENTS

DUROLANE
GEL-ONE
GELSYN-3
SUPARTZ FX
VISCO-3

ANTI-INFECTIVES

ANTIRETROVIRAL AGENTS

§ ANTIRETROVIRAL COMBINATIONS

abacavir-lamivudine
lamivudine-zidovudine
ATRIPLA
BIKTARVY
COMPLERA
DESCOVY
EVOTAZ
GENVOYA
ODEFSEY
PREZCOBIX
STRIBILD
TRIUMEQ
TRUVADA

FUSION INHIBITORS

FUZEON

INTEGRASE INHIBITORS

ISENTRESS
TIVICAY

§ NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

efavirenz
nevirapine
nevirapine ext-rel
EDURANT
INTELENCE

§ NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

abacavir tablet
didanosine
lamivudine
stavudine
zidovudine
EMTRIVA

NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS

VIREAD

§ PROTEASE INHIBITORS

lopinavir-ritonavir solution
KALETRA TABLET
NORVIR
PREZISTA
REYATAZ

ANTIVIRALS

§ HEPATITIS B AGENTS

entecavir tablet
lamivudine
BARACLUDE SOLUTION
VEMLIDY

§ HEPATITIS C AGENTS

ribavirin
EPCLUSA (genotypes 1, 2, 3, 4, 5, 6)
HARVONI (genotypes 1, 4, 5, 6)
VOSEVI [2]

ANTINEOPLASTIC AGENTS

§ ALKYLATING AGENTS

temozolomide

§ ANTIMETABOLITES

capecitabine

HORMONAL ANTINEOPLASTIC AGENTS

ANTIANDROGENS

ERLEADA
XTANDI
ZYTIGA

§ LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONISTS

leuprolide acetate
ELIGARD

IMMUNOMODULATORS

REVLIMID
THALOMID

§ KINASE INHIBITORS

imatinib mesylate
AFINITOR
BOSULIF

CABOMETYX
IBRANCE
IRESSA
KISQALI
KISQALI FEMARA CO-PACK
NEXAVAR
RYDAPT
SPRYCEL
SUTENT
TARCEVA
TYKERB
VOTRIENT

§ MISCELLANEOUS

bexarotene capsule
ODOMZO
ZEJULA
ZOLINZA

CARDIOVASCULAR

ANTILIPEMICS

PCSK9 INHIBITORS

REPATHA

PULMONARY ARTERIAL HYPERTENSION

ENDOTHELIN RECEPTOR ANTAGONISTS

LETAIRIS
OPSUMIT
TRACLEER

§ PHOSPHODIESTERASE INHIBITORS

sildenafil

PROSTACYCLIN RECEPTOR AGONISTS

UPTRAVI

PROSTAGLANDIN VASODILATORS

ORENITRAM

CENTRAL NERVOUS SYSTEM

§ HUNTINGTON'S DISEASE AGENTS

tetrabenazine
AUSTEDO

§ MULTIPLE SCLEROSIS AGENTS

glatiramer
AUBAGIO
BETASERON
COPAXONE
GILENYA
REBIF
TECFIDERA
TYSABRI

ENDOCRINE AND METABOLIC

ACROMEGALY

SOMATULINE DEPOT
SOMAVERT

CALCIUM REGULATORS

PARATHYROID HORMONES

FORTEO
TYMLOS

MISCELLANEOUS

PROLIA

CONTRACEPTIVES

PROGESTIN INTRAUTERINE DEVICES

KYLEENA
MIRENA
SKYLA

FERTILITY REGULATORS

GNRH / LHRH ANTAGONISTS

CETROTIDE

OVULATION STIMULANTS, GONADOTROPINS

GONAL-F
OVIDREL

GAUCHER DISEASE

CERDELGA
CEREZYME

HEREDITARY TYROSINEMIA TYPE 1 AGENTS

ORFADIN

HUMAN GROWTH HORMONES

HUMATROPE

§ UREA CYCLE DISORDERS

sodium phenylbutyrate

MISCELLANEOUS

CYSTAGON

HEMATOLOGIC

HEMATOPOIETIC GROWTH FACTORS

ARANESP
PROCRIT
ZARXIO

HEMOPHILIA A AGENTS

ADYNOVATE
JIVI
KOGENATE FS
KOVALTRY
NOVOEIGHT
NUWIQ

HEMOPHILIA B AGENTS

REBINYN

HEREDITARY ANGIOEDEMA

RUCONEST

IMMUNOLOGIC AGENTS

ALLERGENIC EXTRACTS

ORALAIR

AUTOIMMUNE AGENTS

See Table 1 for Indication Based Coverage Details

ANKYLOSING SPONDYLITIS

COSENTYX
ENBREL
HUMIRA

CROHN'S DISEASE

HUMIRA
STELARA SUBCUTANEOUS #

After failure of HUMIRA

PSORIASIS

HUMIRA
OTEZLA
STELARA SUBCUTANEOUS
TALTZ

PSORIATIC ARTHRITIS

COSENTYX
ENBREL
HUMIRA
OTEZLA

RHEUMATOID ARTHRITIS

ENBREL
HUMIRA
KEVZARA
ORENCIA CLICKJECT
ORENCIA SUBCUTANEOUS
XELJANZ
XELJANZ XR

ULCERATIVE COLITIS

HUMIRA
SIMPONI #

After failure of HUMIRA

ALL OTHER CONDITIONS

ENBREL
HUMIRA

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)

RASUVO

IMMUNOSUPPRESSANTS

§ ANTIMETABOLITES

mycophenolate mofetil
mycophenolate sodium

§ CALCINEURIN INHIBITORS

cyclosporine
cyclosporine, modified
tacrolimus

§ RAPAMYCIN DERIVATIVES

sirolimus tablet
RAPAMUNE SOLUTION

RESPIRATORY

§ CYSTIC FIBROSIS

tobramycin inhalation solution
BETHKIS

PULMONARY ENZYME DEFICIENCY AGENTS

ARALAST NP
GLASSIA
PROLASTIN-C

PULMONARY FIBROSIS AGENTS

ESBRIET
OFEV

SEVERE ASTHMA AGENTS

NUCALA

TOPICAL

DERMATOLOGY

ATOPIC DERMATITIS

DUPIXENT

MOUTH / THROAT / DENTAL AGENTS

PROTECTANTS

MUGARD

QUICK REFERENCE DRUG LIST

A

abacavir tablet
abacavir-lamivudine
ADYNOVATE
AFINITOR
ARALAST NP
ARANESP
ATRIPLA
AUBAGIO
AUSTEDO

B

BARACLUDE SOLUTION
BETASERON
BETHKIS
bexarotene capsule
BIKTARVY
BOSULIF

C

CABOMETYX
capecitabine
CERDELGA
CEREZYME
CETROTIDE
COMPLERA
COPAXONE
COSENTYX
cyclosporine
cyclosporine, modified
CYSTAGON

D

DESCOVY
didanosine
DUPIXENT
DUROLANE

E

EDURANT
efavirenz
ELIGARD
EMTRIVA
ENBREL
entecavir tablet
EPCLUSA
ERLEADA
ESBRIET
EVOTAZ

F

FORTEO
FUZEON

G

GEL-ONE
GELSYN-3
GENVOYA
GILENYA
GLASSIA
glatiramer
GONAL-F

H

HARVONI
HUMATROPE
HUMIRA

I

IBRANCE
imatinib mesylate
INTELENCE
IRESSA
ISENTRESS

J

JIVI

K

KALETRA TABLET
KEVZARA
KISQALI
KISQALI FEMARA CO-PACK
KOGENATE FS
KOVALTRY
KYLEENA

L

lamivudine
lamivudine-zidovudine
LETAIRIS
leuprolide acetate
lopinavir-ritonavir solution

M

MIRENA
MUGARD
mycophenolate mofetil
mycophenolate sodium

N

nevirapine
nevirapine ext-rel
NEXAVAR
NORVIR
NOVOEIGHT
NUCALA
NUWIQ

O

ODEFSEY
ODOMZO
OFEV
OPSUMIT
ORALAIR
ORENCIA CLICKJECT
ORENCIA SUBCUTANEOUS
ORENITRAM
ORFADIN
OTEZLA
OVIDREL

P

PREZCOBIX
PREZISTA
PROCRIT
PROLASTIN-C
PROLIA

R

RAPAMUNE SOLUTION
RASUVO
REBIF
REBINYN
REPATHA
REVLIMID
REYATAZ
ribavirin
RUCONEST
RYDAPT

S

sildenafil
SIMPONI
sirolimus tablet
SKYLA
sodium phenylbutyrate
SOMATULINE DEPOT
SOMAVERT
SPRYCEL
stavudine
STELARA SUBCUTANEOUS
STRIBILD
SUPARTZ FX
SUTENT

T

tacrolimus
TALTZ
TARCEVA
TECFIDERA
temozolomide
tetrabenazine
THALOMID
TIVICAY
tobramycin inhalation solution
TRACLEER
TRIUMEQ
TRUVADA
TYKERB
TYMLOS
TYSABRI

U

UPTRAVI

V

VEMLIDY
VIREAD
VISCO-3
VOSEVI [2]
VOTRIENT

X

XELJANZ
XELJANZ XR
XTANDI

Z

ZARXIO
ZEJULA
zidovudine
ZOLINZA
ZYTIGA

PREFERRED OPTIONS FOR EXCLUDED SPECIALTY MEDICATIONS [3]

DRUG NAME(S)	PREFERRED OPTION(S)*
ADCIRCA	*sildenafil*
ALPROLIX	Consult doctor
BERINERT	RUCONEST
BRAVELLE	GONAL-F
BUPHENYL	*sodium phenylbutyrate*
DAKLINZA	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)
ELELYSO	CERDELGA, CEREZYME
ELOCTATE	ADYNOVATE, JIVI, KOGENATE FS, KOVALTRY, NOVOEIGHT, NUWIQ
EUFLEXXA	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
EXTAVIA	*glatiramer,* AUBAGIO, BETASERON, COPAXONE, GILENYA, REBIF, TECFIDERA, TYSABRI
FASENRA	NUCALA
FOLLISTIM AQ	GONAL-F
GENOTROPIN	HUMATROPE
GLEEVEC	*imatinib mesylate,* BOSULIF, SPRYCEL
HELIXATE FS	ADYNOVATE, JIVI, KOGENATE FS, KOVALTRY, NOVOEIGHT, NUWIQ
HYALGAN	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
LILETTA	KYLEENA, MIRENA, SKYLA
LUPRON DEPOT (For Prostate Cancer Only)	ELIGARD
MAVYRET	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI [2]
MONOVISC	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
NEUPOGEN	ZARXIO
NORDITROPIN	HUMATROPE
NUTROPIN AQ	HUMATROPE
OMNITROPE	HUMATROPE
ORTHOVISC	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
OTREXUP	RASUVO
PEGASYS	Consult doctor
PRALUENT	REPATHA
PROCYSBI	CYSTAGON
PROGRAF	*tacrolimus*
RAVICTI	*sodium phenylbutyrate*
REVATIO	*sildenafil*
SAIZEN	HUMATROPE
SANDOSTATIN LAR	SOMATULINE DEPOT, SOMAVERT
SYNVISC, SYNVISC-ONE	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3
TASIGNA	*imatinib mesylate,* BOSULIF, SPRYCEL
TECHNIVIE	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)
TOBI	*tobramycin inhalation solution,* BETHKIS
TOBI PODHALER	*tobramycin inhalation solution,* BETHKIS
VIEKIRA PAK	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)
VIEKIRA XR	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)
XENAZINE	*tetrabenazine,* AUSTEDO
ZEMAIRA	ARALAST NP, GLASSIA, PROLASTIN-C
ZEPATIER	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)

TABLE 1 - PREFERRED OPTIONS FOR INDICATION BASED AUTOIMMUNE EXCLUDED MEDICATIONS

CONDITION	EXCLUDED DRUG NAME(S)	PREFERRED OPTION(S)
ANKYLOSING SPONDYLITIS	CIMZIA SIMPONI	COSENTYX ENBREL HUMIRA
CROHN'S DISEASE	CIMZIA ENTYVIO	HUMIRA STELARA SUBCUTANEOUS #
PSORIASIS	CIMZIA COSENTYX ENBREL	HUMIRA OTEZLA STELARA SUBCUTANEOUS TALTZ
PSORIATIC ARTHRITIS	CIMZIA ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS SIMPONI STELARA SUBCUTANEOUS TALTZ XELJANZ XELJANZ XR	COSENTYX ENBREL HUMIRA OTEZLA
RHEUMATOID ARTHRITIS	ACTEMRA CIMZIA KINERET ORENCIA INTRAVENOUS SIMPONI	ENBREL HUMIRA KEVZARA ORENCIA CLICKJECT ORENCIA SUBCUTANEOUS XELJANZ XELJANZ XR
ULCERATIVE COLITIS	ENTYVIO XELJANZ	HUMIRA SIMPONI #
ALL OTHER CONDITIONS	ACTEMRA KINERET ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS	ENBREL HUMIRA

After failure of HUMIRA

You may be responsible for the full cost of certain non-formulary products that are removed from coverage. Please check with your plan sponsor for more information.

FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. New-to-market products and new variations of products already in the marketplace will not be added to the formulary immediately. Each product will be evaluated for clinical appropriateness and cost-effectiveness. Recommended additions to the formulary will be presented to the CVS Caremark National Pharmacy and Therapeutics Committee (or other appropriate reviewing body) for review and approval. In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. Specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. The member's prescription benefit plan may have a different copay[1] for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and lowercase *Italics*, and generic products in lowercase *italics*. Generics listed in therapeutic categories are for representational purposes only. Listed products may be available generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to **www.caremark.com** to check coverage and copay[1] information for a specific medicine.

***** The preferred options in this list are a broad representation within therapeutic categories of available treatment options and do not necessarily represent clinical equivalency.

§ Generics are available in this class and should be considered the first line of prescribing.

[1] Copayment, copay or coinsurance means the amount a member is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.

[2] For use in patients previously treated with an HCV regimen containing an NS5A inhibitor (for genotypes 1-6) or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).

[3] An exception process is in place for specific clinical or regulatory circumstances that may require coverage of an excluded medication.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.
CVS Caremark may receive rebates, discounts and service fees from pharmaceutical manufacturers for certain listed products. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

 106-31697C 010119 www.caremark.com